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Abstract
Mitochondrial disorders affect 1/5,000 and have no cure. Inducing
mitochondrial biogenesis with bezafibrate improves mitochondrial
function in animal models, but there are no comparable human
studies. We performed an open-label observational experimental
medicine study of six patients with mitochondrial myopathy
caused by the m.3243A>G MTTL1 mutation. Our primary aim was
to determine the effects of bezafibrate on mitochondrial metabo-
lism, whilst providing preliminary evidence of safety and efficacy
using biomarkers. The participants received 600–1,200 mg bezafi-
brate daily for 12 weeks. There were no clinically significant
adverse events, and liver function was not affected. We detected a
reduction in the number of complex IV-immunodeficient muscle
fibres and improved cardiac function. However, this was accompa-
nied by an increase in serum biomarkers of mitochondrial disease,
including fibroblast growth factor 21 (FGF-21), growth and dif-
ferentiation factor 15 (GDF-15), plus dysregulation of fatty acid
and amino acid metabolism. Thus, although potentially beneficial
in short term, inducing mitochondrial biogenesis with bezafibrate
altered the metabolomic signature of mitochondrial disease, rais-
ing concerns about long-term sequelae.
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Introduction
Mitochondrial diseases are genetically determined metabolic disor-
ders of oxidative phosphorylation (OXPHOS) caused by mutations
of mitochondrial DNA (mtDNA) or nuclear genes encoding mito-
chondrial proteins (Wallace, 2018). As a group, they affect ~ 1 in
5,000 (Gorman et al, 2015). The clinical features involve tissues
with high-energy demands, especially striated muscle and the
nervous system. Mitochondrial diseases cause substantial morbidity
and have no cure.
Several new strategies are being developed as possible treat-
ments for mitochondrial disorders. These include protein replace-
ment; small molecules including antioxidants, amino acids and
nucleotide supplementation; cell therapy; and gene manipulation
(Nightingale et al, 2016). Although pre-clinical studies have seen
the greatest progress, several are now under evaluation in clini-
cal trials (Steele et al, 2017). One approach is to induce mito-
chondrial biogenesis, which is effective in animal models of
mitochondrial diseases (Ahola-Erkkila et al, 2010; Viscomi et al,
2011; Cerutti et al, 2014; Peralta et al, 2016). Several compounds
show promise in pre-clinical studies, including agonists of AMP-
protein activated kinase (Viscomi et al, 2011; Peralta et al,
2016), peroxisome proliferator-activated receptor (PPAR) (Yatsuga
& Suomalainen, 2012; Benit et al, 2017), sirtuins (Cerutti et al,
2014) and Nrf2 (Hayashi et al, 2017). Of these, bezafibrate has
the most extensive pre-clinical evidence of efficacy in animal
models (Dillon et al, 2012) and patient cell lines (Hofer et al,
2014). Bezafibrate has a favourable side-effect profile in humans
but has been noted to cause liver toxicity in rodents, including
mouse models of mitochondrial disease (Viscomi et al, 2011;
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Dillon et al, 2012; Yatsuga & Suomalainen, 2012). We, therefore,
designed an open-label, investigator-led, non-randomised experi-
mental medicine study to evaluate the effects of bezafibrate in
patients with mitochondrial disease. We incorporated detailed
molecular, biochemical and metabolomic profiling alongside clini-
cal measures. Our primary aim was to evaluate the safety of
inducing mitochondrial biogenesis with bezafibrate in patients
with the m.3243A>G MTTL1 mutation. Our secondary aim was
to provide preliminary evidence of efficacy to power a subse-
quent randomised controlled trial.
Results
Participants and treatment
We studied six unrelated adults with mitochondrial myopathy due
to the m.3243A>G MTTL1 mutation in skeletal muscle (50–84%
heteroplasmy, four female, mean age 50 years, range 44–57), identi-
fied from local clinics and the UK MRC Mitochondrial Disease
Cohort. All had clinical evidence of proximal weakness on bedside
testing (Medical Research Council grade 4+ or less). Four had
diabetes and deafness, but no other clinical features of mitochon-
drial disease (Table 1). The entry and exclusion criteria are shown
in Appendix Tables S1 and S2. The standard dose of bezafibrate used
to treat dyslipidemia in the UK is 200 mg three times daily (TDS).
Based on pre-clinical toxicology and efficacy studies in rodents, we
calculated an equivalent dose range (Appendix Table S3) and treated
with 200 mg TDS for 6 weeks, then 400 mg TDS in the absence of
clinical toxicity. The study design is summarised in Fig 1. Needle
muscle biopsies were performed with ethical approval and patient
consent.
Safety and tolerability
All six completed the study and treatment regime. There was no
change in mean body mass index (BMI) during the treatment
(Appendix Table S4). Although there was a trend towards a
reduction in non-fasting triglyceride levels after 12 weeks of
treatment, the mean level across all participants did not change
significantly (Appendix Tables S5). One serious adverse event
was reported: acute abdominal pain due to constipation which
resolved overnight. This is a recognised complication of both
bezafibrate treatment and mitochondrial disease. Four had mild
hypoglycaemia leading to a reduction in the insulin dose in the
three patients with insulin-treated diabetes. The other patient
with mild hypoglycaemia had glucose intolerance under dietary
control. The liver function tests remained normal. Three had a
reversible reduction in estimated glomerular filtration rate
(Fig EV1). FGF-21 and GDF-15 levels were elevated at baseline
and increased further at 6 then 12 weeks with increased dose
(Figs 2A and EV2) irrespective of gender, body mass index, body
surface area or diabetes mellitus (Fig EV3). Unsupervised k-
means clustering of the normalised serum metabolomics data
separated the pre- and post-treatment groups (Group 1 vs.
Groups 2 and 3; Fig EV4A), but there were no differences
between weeks 6 and 12 (Fig EV4B). Investigation of the dif-
ferentially regulated metabolites (Fig 2B, Dataset EV1) and
pathways (Fig 2C, Dataset EV2) highlighted changes in amino
acid metabolism and tricarboxylic acid cycle intermediates (TCA
cycle) between 0 and 6 and 12 weeks of treatment (Fig EV4C
and D).
Biochemistry and genetics
Targeted analysis of acyl-carnitines as a surrogate of b-oxidation
showed a decrease in the levels of C3, C8, C14:1, C16:1, C18, C18:1
and C20 consistent with the induction of fatty acid oxidation on
treatment (Figs 2D, and EV4E and F). At baseline, skeletal muscle
complex I activity was low and complex III and IV activities were
high or similar to control values relative to citrate synthase (Figs 2E
and EV5A). Mean enzyme activities, including citrate synthase, did
not change on treatment (Fig 2E), although there was considerable
variation (Figs 2E, and EV5A and B). Quadruple immunofluores-
cence showed a reduction in the number of complex IV-deficient
muscle fibres after treatment (P-value = 0.048, Fig 3A and B,
Appendix Table S6, not detectable by Western blotting,
Appendix Fig S1). Hierarchical cluster analysis and unsupervised k-
means clustering of the skeletal muscle RNA-seq transcripts did not
discriminate different groups before and after treatment (Fig 3C,
Appendix Fig S2). Surprisingly, the analysis of differentially
expressed transcripts (Dataset EV3) and Reactome Pathway Analysis
(Dataset EV4) showed a significant decrease in genes involved in
oxidative phosphorylation, including MT-ND1, MT-ND2, MT-ND4,
MT-ND-5, and MT-CYB (Fig 3D and E). However, there was no
change in the average mtDNA copy number in skeletal muscle with
treatment (Appendix Fig S3). The mean percentage m.3243A>G
mtDNA heteroplasmy in blood, urinary sediment and skeletal
muscle did not change with treatment, although there was consider-
able variation in urinary sediment measurements (Fig 3F).
Clinical measures
Mean submaximal exercise testing parameters did not change after
treatment. Actigraphy showed no change in accelerometry, activity
or sleep cycles with treatment. There was no difference in the
skeletal muscle 31P-MRS phosphocreatine recovery time (s1/2 PCr),
adenosine diphosphate recovery time (s1/2 ADP), or the ratio (ADP/
PCr) with treatment (Appendix Fig S4). However, treatment was
associated with an increase in end-systolic volume and end-systolic
Table 1. Clinical characteristics of the six patients with the
m.3243A>G MTTL1 mutation and mitochondrial myopathy.
Subject Sex Age
Features
in addition
to myopathy
Symptom
duration
(years)
Baseline
NMDAS
P1 F 52 MIDD 17 36
P2 F 52 9 18
P3 M 44 MIDD 28 33
P4 M 49 11 19
P5 F 57 MIDD 18 21
P6 F 46 MIDD 11 19
MIDD, mitochondrially inherited diabetes and deafness; NMDAS, Newcastle
Mitochondrial Disease Adult Scale.
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Figure 1. Summary of the study design.
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index (Fig 3G). The mean questionnaire scores did not change
following treatment, including the NMDAS and muscle-specific
scores (Appendix Table S7). There was no correlation between the
level of m.3243A>G heteroplasmy or clinical features and the clini-
cal or biochemical responses to treatment.
Discussion
As expected, we detected evidence of on-target effects of bezafibrate
through the induction of fatty acid b-oxidation (Bonnefont et al,
2010) and a trend towards decreased triglyceride levels. However,
even using doses higher than typically used to treat dyslipidaemia,
bezafibrate had a minimal impact on markers of mitochondrial
biogenesis. Similar to other studies using PPAR agonists, we
observed dose-dependent increases in serum GDF-15 and FGF-21
(Inagaki et al, 2007; Yatsuga & Suomalainen, 2012), which have
been proposed as biomarkers of mitochondrial disease (Lehtonen
et al, 2016). This raises the possibility that treatment led to an exac-
erbation of the mitochondrial pathology in patients with the
m.3243A>G mutation, although given the lack of specificity of GDF-
15 and FGF-21, it is also plausible that the changes we observed
were due to the direct effects of bezafibrate on metabolism indepen-
dent of oxidative phosphorylation.
Following bezafibrate treatment, we also saw an alteration of
metabolic pathways involving glutamine metabolism and the
tricarboxylic acid (TCA) cycle (Buzkova et al, 2018), as well as
an increase in the level of several amino acids including histidine,
alanine, aspartate and N-acetyl-aspartate (NAA) (Thompson
Legault et al, 2015). Glutamine is an abundant circulating amino
acid and has an anaplerotic role, replenishing TCA cycle interme-
diates, which drive the mitochondrial respiratory chain to gener-
ate reducing equivalents (Mullen et al, 2014; Chen et al, 2018). In
the context of mtDNA mutations, glutamine is reduced by the
TCA cycle leading to the synthesis of aspartate, which is essential
for nucleotide synthesis (Chen et al, 2018). Thus, increased amino
acid levels, including glutamate, could be part of a compensatory
response to the primary OXPHOS defect (Buzkova et al, 2018;
Chen et al, 2018). Similar findings have been observed for aspar-
tate, with effects on reductive carboxylation (Chen et al, 2018;
Sullivan et al, 2018). Likewise, increased histidine has been
observed in models of mitochondrial disease (Vo et al, 2007;
Chen et al, 2018), where it can act as a source of folate (Mao
et al, 2004) and TCA cycle pre-intermediates such as glutamate,
which are then degraded to a-ketoglutarate (Alifano et al, 1996).
It is therefore possible that bezafibrate provokes or enhances an
endogenous compensatory response to the primary metabolic
defect that resembles a fasting response (Crooks et al, 2014; Tan
et al, 2017), despite the patients being well-nourished throughout,
and with no associated weight loss. However, given the observed
increase in all three amino acids, it remains puzzling that, over-
all, the TCA metabolites decreased on treatment. The reasons for
this are not clear, but could reflect the effects of increased aspar-
tate levels, which are known to inhibit alpha-ketoglutarate utilisa-
tion (Chen et al, 2018), with knock-on effects on other TCA cycle
intermediates.
Our study was not designed to detect significant changes in clini-
cally meaningful parameters, but the data will provide a useful basis
for future power calculations. It is encouraging that we observed an
improvement in parameters of cardiac function on MRI that are
known to be impaired in patients with m.3243A>G (Hollingsworth
et al, 2012). The clinical significance of these findings is unclear at
present, but they support the use of cardiac MRI as a biomarker to
monitor treatment in mitochondrial diseases (Steele et al, 2017),
which is sensitive to changes over a short period and correlates with
the underlying biochemical defect in skeletal muscle (Hollingsworth
et al, 2012).
Importantly, we observed considerable variability in several
proposed biomarkers, including exercise physiology and
m.3243A>G heteroplasmy in urinary sediments, explaining why
these do not always correlate with clinical severity. On the other
hand, being sensitive to changes at the single-cell level, quadruple
immunofluorescence shows promise when compared bulk measures
of respiratory chain protein abundance and function in skeletal
muscle. We did not observe a similar change in either the respira-
tory chain activity or protein abundance on Western blots, probably
because the changes only affected a small proportion of the individ-
ual muscle fibres, and were thus not detectable in an analysis of a
muscle homogenate. Thus, although the quadruple immunofluores-
cence may be a sensitive biomarker indicative of a treatment
response, the clinical significance of these findings remains to be
determined.
◀ Figure 2. Metabolic effects of bezafibrate in patients with the m.3243A>G MTTL1 mutation.W0, W6 and W12 refer to the week of study.
A Serum FGF-21 and GDF-15 levels before, during and after treatment (two-sided Wilcoxon signed-rank test, P-value = 0.031 in all significant cases) (see Fig EV2 for
details where P1–P6 refer to the individual patients).
B Volcano plot showing differences in metabolite levels between 0 and 6 and 12 weeks of treatment. Metabolites in histidine, alanine, aspartate and glutamine
metabolism, and the TCA cycle pathways are annotated at 10% false discovery rate (see Dataset EV1 for the whole list of differentially regulated metabolites.
Although some other metabolites showed a more pronounced difference, these did not fit into a recognised pathway). Metabolite labels are colour-coded according
to the identified KEGG pathways (dark red = “Alanine, aspartate and glutamate metabolism”, dark green = “Histidine metabolism” and dark blue = “Citrate cycle
(TCA cycle)”, with transition colour code if the metabolite belongs to more than one KEGG pathways).
C Scatterplot depicting P-values from the metabolites Pathway Enrichment Analysis (y-axis) and impact values from Pathway Topology Analysis (x-axis) (see Dataset
EV2 for details). KEGG pathways at 10% adjusted Holm–Bonferroni P-value are highlighted.
D Volcano plot of acyl-carnitine metabolites between 0 and 6 and 12 weeks of treatment with highlighted differential metabolites at 10% FDR.
E Respiratory chain complex and citrate synthase activity in skeletal muscle before and after 12 weeks of treatment. No significant differences were detected before
and after 12 weeks of treatment by using the two-sided Wilcoxon signed-rank test with an empirical level of significance.
Data Information: In (A) and (E), horizontal dotted lines denote the mean values in healthy age-matched controls. In (E), solid horizontal lines and bars represent the
mean  SD of the technical replicates at each time point. Horizontal lines on (A) and (E) refer to statistical comparisons of the mean values, where ns = non-significant,
*P-value ≤ 0.05.
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It should be noted that our results are based on observations in a
specific subgroup of patients with mitochondrial disease due to the
m.3243A>G mutation. However, they do suggest that bezafibrate
should be used with caution to treat dyslipidaemia in patients with
mitochondrial disorders. Future studies inducing mitochondrial
biogenesis through PPAR activation should proceed with caution,
with careful monitoring for possible toxicity. Measuring blood meta-
bolomic biomarkers, FGF-21, and GDF-15 in addition to serum crea-
tine kinase would provide some reassurance if levels do not change
on treatment.
Materials and Methods
In overview, the following data were collected: (i) Measures of
safety and tolerability at 0, 6 and 12 weeks including adverse
events, haematological and biochemical blood tests, creatine kinase;
FGF-21, GDF-15 and serum metabolomics; (ii) respiratory chain
enzyme activity in skeletal muscle at baseline and 12 weeks; (iii)
percentage of cytochrome c oxidase (COX) muscle fibres by histo-
chemistry, quantification of respiratory chain complexes I and IV
proteins NDUFB8 and COXI by quadruple fluorescence immunohis-
tochemistry (Rocha et al, 2015) and Western blotting, all at 0 and
12 weeks; (iv) muscle RNA-seq at 0 and 12 weeks; (v) percentage
heteroplasmy of the m.3243A>G in blood and urinary sediment at 0,
6 and 12 weeks, and muscle at 0 and 12 weeks; total mtDNA copy
number in skeletal muscle at 0 and 12 weeks; (vi) submaximal
exercise testing, 31P-magnetic resonance spectroscopy (31P-MRS)
in skeletal muscle, cardiac function by MRI, accelerometry and
activity, timed up and go (TUG), and the following questionnaires:
International Physical Activity Questionnaire (IPAQ), Newcastle
Mitochondrial Disease Adults Scale (NMDAS), the Newcastle Mito-
chondrial Disease Quality of Life Score (NMQ), the Fatigue Impact
Score (FIS), all at 0 and 12 weeks. See the Expanded View docu-
ment for detail methods and citations.
Detailed methods
Serum FGF-21 and GDF-15
Blood samples were collected in a serum-separating tube at times 0,
6 and 12 weeks of the study. Samples were centrifuged at 5,000 g
for 10 min, and the resulting serum was snap frozen. FGF-21 and
GDF-15 were measured by ELISA from BioVendor and R&D systems,
respectively, following manufacturer’s instructions.
Serum metabolomics analysis
Sample preparation, QA/QC and Ultrahigh Performance Liquid
Chromatography-Tandem Mass Spectroscopy (UPLC-MS/MS) were
performed at Metabolon© as well as compound identification, quan-
tification and data curation as described previously (Shin et al,
2014). A total of 867 different metabolites were measured on human
serum from six patients over three-time points at 0 (untreated), 6
and 12 weeks (treated). Among the measured metabolites, only four
were partially characterised (untargeted), whilst known (targeted)
metabolites spanned a wide range of biochemical classed (“super-
pathways”) including 187 “Amino Acid” (22%), 27 “Carbohydrate”
(3%), 28 “Cofactors and Vitamins” (3%), 11 “Energy” (1%), 409
“Lipid” (47%), 37 “Nucleotide” (4%), 37 “Peptide” (4%) and 127
“Xenobiotics” (15%). Normalisation and imputation of serum
metabolites were performed as previously described (Shin et al,
2014; Krumsiek et al, 2015). Briefly, data normalisation (N)
consisted of the following steps: (N.1) partially characterised
metabolites and metabolites belonging to “Xenobiotics” biochemical
class were removed from the analysis, reducing the number of
targeted metabolites to 736; (N.2) each metabolite raw value was
rescaled to have median 1 to adjust for variation due to instrument
run-day tuning differences; (N.3) a log transformation with base 10
was applied to all the metabolites; (N.4) after transformation, data
points lying more than four standard deviations from the mean of
each metabolite concentration were excluded. For the imputation (I)
of missing values, we employed the KNN-TN method (Shah et al,
2017), which consists of the following steps: (I.1) Estimation of the
detection level (DL) of the machine to be the minimum observed
value for the whole dataset; (I.2) maximum likelihood estimation
(MLE) of lm and rm, assuming that each metabolite m
(m = 1,. . .,736) follows a left-truncated (on the DL) Gaussian distri-
bution with mean lm and standard deviation rm; (I.3) standardisa-
tion of each metabolite using the MLEs of lm and rm; (I.4) for each
metabolite m with a missing value in sample i, detection of its
K = 10 closest metabolites (which have an observed value for their
ith sample) using the k-nearest neighbours (KNN) algorithm; (I.5)
imputation of the missing value with a weighted average of the K
values found in (I.4). The weights are functions of the Pearson
correlations between the metabolite with missing values and its K
◀ Figure 3. Mitochondrial biogenesis and clinical effects of bezafibrate in patients with the m.3243A>G MTTL1 mutation.P1–P6 refer to individual patients.
A Representative examples of the quadruple immunofluorescence quantification of skeletal muscle fibres before and after treatment. The box in the top right-hand
corner indicates the normal range, using two antibodies to NDUFB8 and COX I.
B Quantitative quadruple immunofluorescence of skeletal muscle fibres in the six patients showing a decrease (two-sided Wilcoxon signed-rank test with an empirical
level of significance) in the proportion of complex IV-deficient skeletal muscle fibres before and after 12 weeks of treatment (empirical P-value = 0.048).
C Hierarchical cluster analysis of skeletal muscle RNA-seq transcripts before and after treatment showing no clear separation between untreated and treated patients.
D Volcano plot depicting differentially expressed RNA-seq genes at 10% FDR after 12 weeks of treatment. Significantly different mammalian mitochondrial genes
(MitoCarta 2.0) are annotated.
E Reactome Pathway Analysis of the differentially expressed genes at 10% FDR after 12 weeks of treatment (see Expanded View document for details).
F Percentage level m.3243A>G in blood, urinary sediment and skeletal muscle. No differences were detected by using the two-sided Wilcoxon signed-rank test with an
empirical level of significance. W = week of the study.
G Cardiac parameters before and after treatment (two-sided Wilcoxon signed-rank test with an empirical level of significance). ES = end-systolic volume (ml) (empirical
P-value = 0.047) and index (ml/m2) (empirical P-value = 0.046), measured by MRI. Horizontal lines on (B), (F) and (G) refer to statistical comparisons of the mean
values, where ns = non-significant, *P-value ≤ 0.05. For normal reference ranges, see Hollingsworth et al (2012).
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closest metabolites; (I.6) transformation of each metabolite back to
the original scale as it was before step (I.3).
Differential analysis of 736 targeted serum metabolites was
performed by using Limma (Ritchie et al, 2015) after correcting for
treatment time points (0, 6 and 12 weeks) using a linear mixed
model with treatment time points as a random effect. For each
contrast (6- and 12-week treatment vs. untreated, 6-week treatment
vs. untreated, 12-week treatment vs. untreated, and 12-week treat-
ment vs. 6-week treatment), significant differential metabolites
were declared at 10% FDR (Benjamini et al, 2001). 267 (36%)
significant differential metabolites were discovered at 10% FDR in
the 6- and 12-week treatment vs. untreated contrast. Pathway
Enrichment Analysis was performed by using MetaboAnalyst 4.0
(Chong et al, 2018) with 176 (23%) significant differential metabo-
lites mapped in KEGG pathways. Given the lack of pathways anno-
tation for a large fraction of differential metabolites, significantly
enriched pathways were declared at a conservative 10% Holm–
Bonferroni correction. Finally, Pathway Topology Analysis was
performed by selecting the relative-betweenness centrality measure
(ranging between 0 and 1), which quantifies the importance of a
subgroup of metabolites in a given metabolic pathway. Residuals
from the linear mixed model were also used to perform the k-
means unsupervised clustering of the participants’ treatment time
points.
Respiratory chain enzyme activity and citrate synthase activity
The activities of mitochondrial respiratory chain enzymes and the
matrix marker citrate synthase were determined spectrophotometri-
cally in skeletal muscle homogenates as described, within a UKAS-
accredited (ISO 15189) laboratory (Kirby et al, 2007).
Immunoblot analysis
Approximately 25–45 mg of snap frozen muscle was lysed in RIPA
buffer (10×) (Sigma) buffer containing 1× cOmpleteTM protease inhi-
bitor (Roche). Samples were homogenised using a Precellys24
mechanical tissue homogeniser and centrifuged at 14,000 g for
10 min at 4°C. The supernatant, containing the soluble protein, was
kept. Protein concentration in each sample was determined using
the PierceTM BCA Protein Assay Kit (Thermo Fisher) using manufac-
turer’s instructions. In each electrophoresis, 20 lg of each sample
was loaded NuPAGE Bis-Tris Precast Midi Protein Gels with MES
(Invitrogen) following the manufacturer’s conditions. SeeBlue
Plus2 Pre-stained Protein Standard from Invitrogen was used in
each electrophoresis as protein size marker. The separated proteins
were transferred to polyvinylidene fluoride membranes using the
iBLOT system (Invitrogen). The resulting blots were probed over-
night at 4°C with primary antibodies with the appropriate concentra-
tion following manufacture’s condition with small adaptations.
Briefly, OXPHOS Human WB Antibody Cocktail Complex Ab110411
(1:250) and Porin/VDAC1 Ab434 (1:1,000). After the primary anti-
body, blots were incubated for 1 h with secondary antibodies [IR
Dye 680 Goat anti-Rabbit Li-Cor #A32729 (1:2,000) and IR Dye
680RD Goat Anti Mouse Li-Cor 926-68070 (1:1,000)] and the
membrane was imaged using the Li-Cor Odyssey CLx Imager.
The bands for each antibody were quantified, aligned and cropped
using bands that were quantified using the Li-Cor Odyssey CLx
Imager inbuilt analysis software, and the OD was used as a value
for statistical purposes. OD values corrected by porin in each case.
Muscle histochemistry and immunocytochemistry
Sequential COX/SDH histochemistry (COX/SDH) and quantitative,
quadruple immunofluorescence were carried out according to estab-
lished, clinically validated protocols within a UKAS-accredited (ISO
15189) laboratory (Old & Johnson, 1989; Rocha et al, 2015).
RNA-seq analysis
Total RNA was extracted from muscle samples using RNeasy
Mini Kit as per manufacturer’s instructions (Quiagen, UK). RNA
integrity and quantity were assessed by RNA ScreenTape Analy-
sis (Agilent). Samples with RIN number higher than 8.5 were
used for RNA-seq. RNA-seq was performed with TruSeq Stranded
Total RNA with RiboZero following manufacture’s conditions.
Counts from the raw RNA-seq bezafibrate FastQ files were gener-
ated via Salmon (Patro et al, 2017), which also maps the reads
to the reference transcriptome. Annotation of the genes was
obtained by using the R package biomaRt (Durinck et al, 2009),
whilst the list of mammalian mitochondrial genes was down-
loaded from MitoCarta2.0 (Calvo et al, 2016). Normalisation and
filtering of raw count data were performed by using the R pack-
age edgeR (Robinson et al, 2010). Since the ratio of the largest
library size to the smallest is less than 3-fold (1.31), mean–
variance relationship is modelled with an empirical Bayes prior
trend with read counts converted to log2-counts-per-million (log
CPM). Log CPM gene expression measurements were used to
perform the k-means unsupervised clustering of the participants’
treatment time points.
Differential analysis of log CPM gene expression (see Table E5)
was performed by using Limma (Ritchie et al, 2015) with paired
blocking (12-week treatment vs. untreated). Significant differential
genes were declared at 10% FDR (Benjamini & Hochberg, 1995).
Pathway analysis was performed by Reactome (Fabregat et al,
2018).
Molecular genetics
Total DNA was extracted from skeletal muscle (tibialis anterior),
urinary sediment, and blood using DNeasy Blood & Tissue Kit
following manufacturer’s instructions (Quiagen, UK). Measurement
of m.3243A>G heteroplasmy (de Laat et al, 2016) and mtDNA levels
(Pyle et al, 2015) were quantified following previously reported
methods.
Cardiac MRI
Participants were imaged supine using a 6-channel cardiac coil
and ECG gating. Long axis 4 chamber views and a short axis
stack with balanced steady-state free precession images obtained
during breath-holding and covering the entire left ventricle (field
of view (FOV) 350 × 350 mm2, repetition time/echo time (TR/
TE) = 3.7/1.9 ms, turbo factor 17, flip angle (FA) 40°, slice thick-
ness 8 mm, 25 phases, resolution 1.37 mm) were acquired. Image
analysis was undertaken using the cardiac analysis package of
the ViewForum workstation (Philips, Best, NL). Manual tracing of
the epicardial and endocardial borders was performed on the
short axis slices at end-systole and end-diastole. Left ventricular
mass, ejection fraction, end-systolic and end-diastolic parameters
were calculated. The eccentricity ratio was calculated as the ratio
of LV mass to end-diastolic volume, with increased values
demonstrating the presence of concentric remodelling. To
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standardise measurements for participant size, body surface area
was calculated using subjects’ weight and height (Du Bois & Du
Bois, 1989).
Clinical rating scales
International Physical Activity Questionnaire (IPAQ), Newcastle
Mitochondrial Disease Adults Scale (NMDAS), the Newcastle Mito-
chondrial Disease Quality of Life Score (NMQ), the Fatigue Impact
Score (FIS) (Schaefer et al, 2006).
Cycle ergometry
All individuals followed the same exercise protocol using an elec-
tronically braked cycle ergometer (Corival Lode BV, Groningen,
The Netherlands) and gas analysis system (Metalyzer 3B; Cortex,
Leipzig, Germany). Cardiac output was measured using validated
bioreactance techniques (NICOM, Cheetah Medical, Delaware,
USA) using two electrodes placed over the trapezius muscle on
either side of the torso; and two placed on the lower posterior
torso lateral to the margin of the latissimus dorsi muscle (Jones
et al, 2015). Prior to exercise testing, participants underwent a
12-lead electrocardiogram (ECG; Custo med GmbH, Ottobrunn,
Germany) and blood pressure monitoring (Suntech Tango+,
Suntech Medical Ltd, Oxford, UK) in a semi-recumbent seated posi-
tion. Expired gases and cardiac output were collected for at least
5 min at rest. During exercise testing, the ECG and cardiac output
were monitored continuously and blood pressure was measured
every 2 min. Both ECG and blood pressure (BP) were monitored
for at least 5 min after the exercise test had been terminated in
order to monitor participant recovery. Participants undertook a
maximal graded cardiopulmonary exercise stress test using an
incremental protocol of 10 W/min. Participants were requested to
maintain a cadence of 60 rpm on the ergometer. In order to avoid
influencing the results of repeat exercise testing at week 12, the
baseline test results were not available to the investigators for
review until after the second test. The exercise test was terminated
by the presence of severe dyspnoea; muscle fatigue; physical
exhaustion (defined as a respiratory exchange ratio > 1.1; or Borg
RPE (Rating of Perceived Exertion) score > 18; or failure to
increase oxygen consumption despite increasing exercise intensity)
or where participants were unable to maintain requested cadence
despite encouragement. Valid tests were those terminated due to
physical exhaustion as defined above. Peak oxygen consumption
and peak work rate were defined as average values over the last
30 s of the exercise (before termination of the test). Cardiac output
(CO) was calculated as the product of stroke volume (SV) and
heart rate (HR), and the arterial-venous difference (a-VO2 diff) was
calculated as the ratio between oxygen consumption and cardiac
output.
Accelerometry
Physical activity was measured using a tri-axial accelerometer
(GENEActiv, Activinsights Ltd, UK) worn at the wrist for seven
consecutive days on three occasions over the study: (i) between
screening and baseline visits; (ii) between weeks five and six; (iii)
and between weeks 11 and 12. Participants were instructed to
wear the devices at all times during the 7-day monitoring period
including whilst sleeping, bathing or showering and requested that
the device be worn on the same wrist at each of the three
measurement times. The sampling frequency was set to 50 Hz.
Raw accelerometry data were run through R-package GGIR version
1.2.8 (www.cran.r-project.org). The first and last hour of the
measurement was excluded as they are expected to be influenced
by the monitor distribution and collection procedure (van Hees
et al, 2013, 2015). Criteria for valid wear were pre-defined as a
minimum of 16 h of data per day of wear, with at least 5 of the
7 days meeting these criteria, and at least one of these days being
a weekend. Any monitor non-wear detected was imputed using
available data from a similar time-period (e.g. day or night) and
type of day (weekend or weekday). Captured data enabled assess-
ment of: acceleration (milligravity, where 1 mg = 0.001 g =
0.001 × 9.8 m/s2 = 0.001 × gravitational acceleration); activity
duration (time) spent in different intensities (sedentary, light,
moderate, vigorous); sleep duration, sleep efficiency and wake
time overnight. Light, moderate and vigorous activity was
calculated using ≥ 40, ≥100 and ≥ 120 mg cut-offs, respectively
(Charman et al, 2016).
Timed up and go
Participants were assessed at weeks 0, 6 and 12. Participants were
instructed to sit in a standard chair kept in MoveLab and provided
with standardised instructions: “When I say ‘go’ I want you to stand
up and walk to the line, turn, walk back to the chair and sit down
again. Walk at your normal pace”. Subjects were timed from being
told to “go” until their return to a seated position. The test was
repeated three times at each assessment. Statistical analysis was
undertaken using IBM SPSS, version 23 (SPSS Inc., Chicago, IL,
USA).
Statistical and bioinformatic analysis
Statistical testing was performed by using the Wilcoxon signed-rank
test (paired data), the Mann–Whitney test, both with an empirical
level of significance (Hollander & Wolfe, 1973), and the Kruskal–
Wallis test followed by the Tukey honest significant differences test
on the ranked data if the null hypothesis of Kruskal–Wallis test was
rejected (Yandell, 1997). All statistical tests are two-sided. Permuta-
tion test for the Mann–Whitney test was conducted using the R
package coin (Hothorn et al, 2008). For the Wilcoxon signed-rank
test (paired data), we implemented an in-house procedure which
flips at random for each patient the observations at different time
points preserving the paired nature of the data. Given the small
number of combinations (6! = 720), we calculated the exact empir-
ical null distribution. The empirical P-value was obtained by count-
ing the number of times the Wilcoxon signed-rank test statistic
based on the observed data was greater than the same test statistic
on the permutated data.
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The study was registered in advance on ClinicalTrials.gov
(NCT02398201) and EudraCT (2015-000508-24), with Newcastle
upon Tyne Hospitals NHS Trust as sponsor. Ethical approval was
provided by Newcastle and North Tyneside 1 National Research
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Data availability
The datasets produced in this study are available in the following
databases: RNA-Seq data: SRA accession number PRJNA608421.
Expanded View for this article is available online.
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